TLSA — Tiziana Life Sciences

Company context · prepared 2026-08-10 · company sweep 2026-08-07, current per 02-connectors.md § Company-sweep currency and extended 2026-08-10 with the three v5.6.0 company-tier rows · USD · framework v5.6.0

How to read this. Written for a reader who has not studied pharmacology or finance. General terms are defined once in framework/04-glossary.md. Tags: [VERIFIED — source] / [UNVERIFIED] / [WEB ESTIMATE — source, date].

Program analyses for this company are the sub-folders listed in C.2.

C.0 Company-tier coverage — CLEARED

An empty result that the connector genuinely returns still counts as CALLED (framework/02-connectors.md § Three states). No mandatory company-tier tool read NOT CALLED, so the company tier is CLEARED.

C.1 What the company is

Tiziana Life Sciences is a micro-capitalisation biotechnology company headquartered in London and listed on the Nasdaq Capital Market [VERIFIED — BPIQ fetch_company_info 2026-08-10]. It develops one molecule across many diseases: intranasal foralumab (also called TZLS-401 and NI-0401), a fully human antibody directed at the CD3 protein on T cells [VERIFIED — ChEMBL CHEMBL1743020, molecule type Antibody, USAN stem "-mab (-umab)" meaning fully human, 2026-08-10]. Six of the seven programs in the pipeline table below are that same molecule in different indications, which makes Tiziana a single-asset company in substance even though it reports seven programs. A second antibody, the anti-interleukin-6-receptor antibody TZLS-501, was announced in December 2025 for spin-out into a separate listed company [VERIFIED — company PR 2025-12-02, BPIQ press feed]. The company has no product revenue.

Share price (spot): $1.00, read 2026-08-10 [VERIFIED — BPIQ fetch_company_info 2026-08-10, last_price; the Yahoo quote confirms the 2026-08-07 session closed at $1.00]. This is the price every program-level scenario under this ticker is measured against. The move from the previous close of $0.97 (+2.6%, on 982,253 shares — about 2.7× the trailing 60-bar average dollar volume) came on the CEO-purchase disclosures below, not on clinical news. The committed price cache’s most recent bar is 2026-08-05 at a $0.99 close [VERIFIED — data/prices/TLSA.json, read with lib/prices.mjs]; the cache is three trading days behind the live quote, and both figures are reported rather than reconciled.

C.2 Pipeline — every program

Every row returned by BPIQ fetch_company_drugs on 2026-08-10, including the rows with no catalyst. The seven rows are identical in substance to the 2026-08-07 sweep.

Concentration. Foralumab occupies six of the seven rows. Only two rows carry has_catalyst: true — na-SPMS (13497) and Alzheimer’s (17171) — and only one of those, na-SPMS, has any dating better than a period-end placeholder. No row is marked Failed by BPIQ, but three of the seven (Crohn’s disease, COVID-19 and milciclib) have had no recorded activity for two to three years and their registered trials were withdrawn before enrolling a patient — that is a discontinuation in substance even where the BPIQ stage label has not been updated to say so [VERIFIED — ClinicalTrials.gov NCT05028946, NCT04983446, both WITHDRAWN with enrolment 0, 2026-08-10].

C.3 Financial position

The going-concern qualification is still the single most important company-level fact on this page. It is unchanged from the 2026-08-07 sweep. A going-concern qualification is a statement by the company’s auditors that, on the company’s own projections, it does not have the money to meet its obligations for the next twelve months without raising more. It makes a financing before or immediately after the next readout close to unavoidable, whichever way that readout goes.

Shelf and at-the-market capacity — read from the filings for the first time this sweep. The live shelf is an F-3 (registration 333-286064) filed 2025-03-24 and effective 2025-03-27, covering up to $250M of securities, of which up to $100M is a sales-agreement prospectus for an at-the-market facility with Jefferies LLC under an Open Market Sale Agreement dated 2024-10-24 at a 3% commission [VERIFIED — SEC EDGAR, F-3 333-286064, read 2026-08-10]. Two details the summaries this document previously relied on never carried: the company disclosed that it sold 2,600,942 shares under the ATM after its prior registration statement had expired (through 2026-03-06 at about $1.38 average, $3.6M gross) and that those sales “may have been sold in violation of federal and state securities laws and may be subject to rescission rights”; and ATM usage of 5,385,115 shares for $6.4M was on record by the F-3 date [VERIFIED — the F-3's own risk factors and capitalisation section]. One constraint sits near current prices: the January 2026 prospectus supplement computed the public float at 76,474,803 non-affiliate shares ($149M at the then-$1.95 reference price); at today’s $1.00 that same count is worth about $76M, almost exactly the $75M General Instruction I.B.5 line below which future shelf takedowns are capped at one-third of float per twelve months [VERIFIED — 424B5 of 2026-01-22, cover page; the threshold test is made at the time of each takedown, so this is proximity, not a breach].

Dilution history.

A raise before or soon after the next catalyst is close to certain, and the at-the-market facility means part of it can happen without a press release. The January 2026 offering priced at $1.25, 25% above today’s $1.00, and the chief executive’s August purchases priced at $0.97–$1.00, at spot — the company has already once withdrawn an offering rather than price it lower, which is a fact about management’s willingness to dilute at these levels, not a promise about the future.

C.4 Valuation frame

The shares sit near the bottom of their own one-year range, but for the first time since this ticker entered the corpus they have moved: $0.97 → $1.00 (+3.1%) across 2026-08-06/07, on roughly 2.7× average dollar volume, with the disclosed cause being the CEO’s third consecutive session of open-market buying rather than clinical news. Three days ago this page said “there has still been no run-up into the readout”; the honest statement today is that a very small one may have started, from insider buying, five weeks before the readout window opens. Cash per share of at most about six cents still means effectively none of the ~$127M market capitalisation is asset backing; it is all option value on foralumab.

The 52-week range and the position within it are derived from the committed daily price cache rather than captured once, so both are recomputable for any past date. This row is the run-up baseline for every program under this ticker.

C.5 Ownership and flow

The insider flow is continuous, one-directional, concentrating — and, for the first time, read from structured filings rather than press headlines. The EDGAR submissions feed carries nine Section 16 filings in 2026; the five purchase transactions since June, from the Forms 4 themselves:

[VERIFIED — SEC EDGAR Forms 4/4A, accns 0001213900-26-085710, -085950, -086696, -086697, read 2026-08-10]. The chief executive buying ~$1M of stock in the open market across the three sessions immediately preceding this analysis, five to six weeks before the readout window opens, is the single strongest positioning signal on this ticker, and it is now dated, priced and coded rather than qualitative. High insider ownership still cuts both ways: it signals belief, and it shrinks the free float, which makes the shares move further in both directions on the same amount of buying or selling.

C.6 Options chain and its readability

The chain still cannot price this event, and quoting an implied move from it would be false precision — and a second, independent source now agrees. The lowest strike listed anywhere on the chain is $2.50, which is 2.5× the $1.00 spot. There is no strike near the money, so no at-the-money straddle exists and no implied move can be computed.

One thing the chain does say in plain language, even though it cannot price the event: the only options anyone is buying are $2.50 calls, concentrated in the December expiry that spans the readout window. Those calls trade at ten to twenty-five cents. That is a lottery ticket on a 2.5× move rather than a hedge, and it is consistent with a shareholder base that treats the name as binary. Do not convert it into a percentage.

C.7 Reaction to past catalysts

Intraday moves from intra_day_price_change_percent, each cross-checked against the same-day press-release feed. open_price_gap_percent is not used, per the known bug in 02-connectors.md. No new catalyst row since 2026-07-31; the table is reused from the 2026-08-07 sweep, current per § Company-sweep currency.

Read: the reaction function has decayed to near zero, and the decay is monotonic. Through 2024 and early 2025, any foralumab headline — a site opening, a preclinical mouse study, a regulatory filing — was worth between +7% and +27%. Across 2026 the same class of news is worth between −1% and +4.5%. Two of the negative 2026 prints are explained by the IL-6 spin-out and offering overhang rather than by the clinical news they sit on, and are not evidence that good news is punished. What the sequence does establish is that incremental biomarker and milestone announcements no longer move this stock, which is a different regime from the one the 2024–2025 rows describe. The nearest useful inference for a controlled readout is that none of these rows is comparable to one: every row above is an uncontrolled or procedural item, and the company has never reported a placebo-controlled result. The +3.1% two-session move into 2026-08-07 on insider buying (C.1, C.5) is positioning flow, not a catalyst reaction, and does not join this table.

C.8 Company data-quality flags

• The BPIQ market_cap previous-close bug did not reproduce this sweep. Today’s value (127,259,128) divided by the $1.00 last_price gives exactly the implied 127.26M share count, while dividing by the $0.97 previous close would imply 131.2M shares no filing supports. On 2026-08-07 the same field was demonstrably computed off the previous close. The bug is therefore intermittent, which is worse than stable: the field cannot be trusted either way without recomputation, and C.4 recomputes it from the EDGAR-filed share count regardless.
• max_52_week_position (0.07831) also matches the last-price computation this sweep, where prior sweeps documented it on the previous close. Same intermittency; C.4 does not read the field at all, deriving the range and position from data/prices/TLSA.json with lib/prices.mjs.
• BPIQ ttm_burn flipped sign: −8,749,000 this sweep versus +8,749,000 on 2026-08-07, same magnitude. Read as a sign-convention change, not a doubling of information; the magnitude is used and the flip is flagged.
• BPIQ enterprise_value is unstable: $128.2M (above market cap) on 2026-08-07, $124.98M (below it) on 2026-08-10, with no financing event between. The implied debt figure swung from +$8.8M to −$2.3M in three days. C.3 leans on the FY2025 filing’s balance-sheet arithmetic instead.
• BPIQ fetch_company_insider_transactions returned no rows again on 2026-08-10 — ten attempts across four sweeps, zero rows — while EDGAR carries five Form 4 purchase transactions filed 2026-08-05 to 2026-08-07 in the same window. The v5.6.0 EDGAR submissions row now carries the insider flow (C.5), turning what three sweeps of this document called a qualitative press-feed reading into structured, dated, priced, coded transactions. The connector gap itself stands and is unchanged.
• The press feed miscategorised an insider transaction that the filings correct. Stock Titan’s 2026-07-23 headline described Cerrone’s 42,357 shares as “awarded”; the Form 4/A of 2026-08-07 states the amendment exists “solely to correct … the transaction code associated with this open market purchase”. A press-headline reading of insider flow got the kind of transaction wrong; the structured filing is authoritative.
• The January 2026 offering’s share count disagrees between the closing release (7.04M shares) and the final 424B5 (8,800,000 shares), both at $1.25. The XBRL share-count bridge (120.51M + ~7.04M ≈ BPIQ’s implied 127.26M) sides with the release figure. Reported, not resolved.
• The two burn rates disagree by 2.4×. BPIQ ttm_burn gives $8.75M for the trailing twelve months; the FY2025 annual report gives $21.1M of operating expenses and an $18.4M net loss. Part of the gap is likely non-cash, but the two cannot be reconciled from the connector alone, so C.3 reports the runway as a range and leans on the auditors’ going-concern statement.
• The catalyst date still disagrees with itself inside a single BPIQ row. For bpiq_drug_id 13497 the structured catalyst_date_text field reads “Late Q3 2026” while the same row’s note, dated 2026-06-25, reads “Topline late Q3/early Q4 2026; ACTRIMS/ECTRIMS Oct 2026” — the fourth consecutive sweep on which the structured field is one update stale. Reported in full in the program document rather than resolved here.
• BPIQ catalyst_date for row 13497 (2026-09-30) is a period-end placeholder, not a disclosed day, per rule 23. It is not used for timing anywhere; the program’s own readout.window is.
• BPIQ short_float units are now confirmed as percent of float by the FINRA cross-division (C.5) — the first time this corpus has been able to say so. The remaining caveat is which float estimate BPIQ divides by, which is why C.5 reports the FINRA share count and days-to-cover as the authoritative reading.
• monthly_burn, qtr_burn and finance_updated_at all returned null this sweep, as on every prior sweep. The monthly figure here is recomputed from ttm_burn.
• Company financial figures taken from the FY2025 Form 20-F’s income statement and balance sheet are still read from third-party summaries and tagged [WEB ESTIMATE]. The share count, the shelf capacity, the ATM terms and the insider flow are no longer in that category: as of this sweep they are read from the filings themselves via the three v5.6.0 EDGAR/FINRA rows.